Search

Your search keyword '"Huhn, Andrew S."' showing total 62 results

Search Constraints

Start Over You searched for: Author "Huhn, Andrew S." Remove constraint Author: "Huhn, Andrew S." Topic opioid-related disorders Remove constraint Topic: opioid-related disorders
62 results on '"Huhn, Andrew S."'

Search Results

1. The association of pain impact and sleep disruption with opioid withdrawal during opioid-use disorder treatment.

2. Intersectional Risk and the Significant Gap in Care for Persons With Co-occurring Chronic Pain and Opioid Withdrawal.

3. Harm Reduction for Opioid Use Disorder: Strategies and Outcome Metrics.

5. The impact of opioid-stimulant co-use on tonic and cue-induced craving.

6. A double-blind, randomized, placebo-controlled, pilot clinical trial examining buspirone as an adjunctive medication during buprenorphine-assisted supervised opioid withdrawal.

7. Opioid Use Disorder Treatment in the Fentanyl Era.

8. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.

9. Wireless electroencephalography (EEG) to monitor sleep among patients being withdrawn from opioids: Evidence of feasibility and utility.

10. Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.

11. Early Childhood Behavioral and Academic Antecedents of Lifetime Opioid Misuse among Urban Youth.

12. The association of chronic pain and opioid withdrawal in men and women with opioid use disorder.

13. Patient perceptions of higher-dose naloxone nasal spray for opioid overdose.

14. Integration of Patient-reported Outcomes Assessment Into Routine Care for Patients Receiving Residential Treatment for Alcohol and/or Substance Use Disorder.

15. Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl.

16. Positive associations between cannabis and alcohol use polygenic risk scores and phenotypic opioid misuse among African-Americans.

17. Substance Use in the Performing Artist with Chronic Pain.

18. Latent trajectories of anxiety and depressive symptoms among adults in early treatment for nonmedical opioid use.

19. Worsening sleep quality across the lifespan and persistent sleep disturbances in persons with opioid use disorder.

20. Clinical correlates of drug-related dreams in opioid use disorder.

21. Comprehensive pain management as a frontline treatment to address the opioid crisis.

22. Reregulation of cortisol levels and sleep in patients with prescription opioid use disorder during long-term residential treatment.

23. Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone.

24. Provider Continuity in the Prescribing of Buprenorphine/Naloxone Within Medicare Part D.

25. Familial perceptions of appropriate treatment types and goals for a family member who has opioid use disorder.

26. A preliminary examination of the multiple dimensions of opioid craving.

27. Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.

28. Challenges for Women Entering Treatment for Opioid Use Disorder.

29. Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome.

30. Protracted renal clearance of fentanyl in persons with opioid use disorder.

31. Differences in Availability and Use of Medications for Opioid Use Disorder in Residential Treatment Settings in the United States.

32. Preliminary evidence of different and clinically meaningful opioid withdrawal phenotypes.

33. Craving and opioid use disorder: A scoping review.

34. Differential adoption of opioid agonist treatments in detoxification and outpatient settings.

35. Increased neural activity in the right dorsolateral prefrontal cortex during a risky decision-making task is associated with cocaine use in methadone-maintained patients.

36. Non-Opioid Neurotransmitter Systems that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human Evidence.

37. Randomized comparison of two web-based interventions on immediate and 30-day opioid overdose knowledge in three unique risk groups.

38. The relationship between pupil diameter and other measures of opioid withdrawal during naloxone precipitated withdrawal.

39. Review: Sex-Based Differences in Treatment Outcomes for Persons With Opioid Use Disorder.

40. Recovery Goals and Long-term Treatment Preference in Persons Who Engage in Nonmedical Opioid Use.

41. Prefrontal cortex response to drug cues, craving, and current depressive symptoms are associated with treatment outcomes in methadone-maintained patients.

42. Analgesic Effects of Hydromorphone versus Buprenorphine in Buprenorphine-maintained Individuals.

43. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder.

44. Double jeopardy: a review of weight gain and weight management strategies for psychotropic medication prescribing during methadone maintenance treatment.

45. Serious About the Opioid Epidemic? Expand Medicaid.

46. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use.

47. Why aren't physicians prescribing more buprenorphine?

48. Ecological momentary assessment of affect and craving in patients in treatment for prescription opioid dependence.

49. Methadone maintenance patients lack analgesic response to a cumulative intravenous dose of 32 mg of hydromorphone

50. Individuals with Chronic Pain Who Misuse Prescription Opioids Report Sex-Based Differences in Pain and Opioid Withdrawal.

Catalog

Books, media, physical & digital resources